AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 ...

The UK’s largest listed companies are turning their heads towards the glimmer of the Nasdaq after growing impatient ...

AstraZeneca has reported a jump in quarterly sales thanks to record growth in its all-important US business, as the UK’s biggest drugmaker prepares to invest billions in the market ahead of potential ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

LONDON] British pharmaceutical giant AstraZeneca on Tuesday (Jul 29) said net profit rose 27 per cent in the second quarter, ...

Total revenue rose 11 per cent to $28bn (£12.98bn) in the first half of the year, driven by double-digit growth in Oncology ...

On a per-share basis, the Cambridge, Britain-based company said it had net income of 79 cents. Earnings, adjusted for non-recurring costs, came to $1.09 per share. The results met Wall Street ...

While value has outperformed growth in Europe over the past five years, Europe now represents less than half of equity market ...

Merck is a strong and profitable pick meeting Benjamin Graham's criteria. Read more on why investors need to stay aware of ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

The US, a critical market for the pharmaceutical industry, accounted for 44% of AstraZeneca’s total revenue in the second quarter, with US revenue jumping a record 13%. The company expects half of its ...